Clinical Trial Detail

NCT ID NCT01901146
Title Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Subjects With HER2 Positive Early Breast Cancer (Lilac)
Recruitment Completed
Gender female
Phase Phase III
Variant Requirements Yes
Sponsors Amgen
Indications

Her2-receptor positive breast cancer

Therapies

Cyclophosphamide + Epirubicin

Paclitaxel + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST